Merit Medical Reports Results For Fourth Quarter and Year Ended December 31, 2023 - Issues Fiscal Year 2024 Guidance
- Positive: Revenue increased by 10.6% year-over-year in Q4 2023
- Positive: Achieved an 8.3% growth in constant currency revenue
- Positive: Non-GAAP operating margin improved to 18.2%
- Positive: Strong free cash flow generation of $55 million in Q4 2023
- Positive: Completed the Foundations for Growth Program successfully
- Negative: GAAP EPS declined from $0.58 in Q4 2022 to $0.47 in Q4 2023
- Negative: Merit's total debt obligations increased to $846.6 million as of December 31, 2023
- None.
Insights
The reported revenue increase of 10.6% year-over-year for Q4 2023 indicates a strong performance by Merit Medical Systems, particularly in a healthcare technology market that often faces regulatory and reimbursement pressures. This growth, coupled with an 8.3% year-over-year increase in organic constant currency revenue, suggests effective market penetration and the successful integration of acquired interventional products from AngioDynamics.
However, a notable point of concern is the decline in GAAP EPS from $0.58 in Q4 2022 to $0.47 in Q4 2023. This decline could be attributed to various factors, including increased operating costs or investment in research and development, which are not detailed in the provided data. It is essential to understand the underlying reasons for this earnings contraction, as it could signal issues that may affect future profitability.
Merit's guidance for fiscal year 2024, projecting a 4-5% increase in revenue and a 9-11% rise in non-GAAP EPS, reflects confidence in the company's ability to maintain growth momentum. The introduction of the 'Continued Growth Initiatives' Program with targets set for 2026 demonstrates a long-term strategic vision that could be reassuring to investors.
The healthcare technology sector is rapidly evolving, with a growing emphasis on minimally invasive procedures, which is likely benefiting Merit's cardiovascular and endoscopy segments. The reported revenue growth in these segments, particularly the 19.4% increase in the cardiovascular peripheral intervention product line, indicates a robust demand for Merit’s offerings.
Moreover, the emphasis on free cash flow, with $55 million generated in Q4 and over $110 million for the year, is a critical metric for investors. It demonstrates Merit's ability to convert earnings into cash effectively, which is crucial for funding operations, paying down debt and pursuing strategic initiatives without diluting shareholder value through equity financing.
From a market perspective, Merit's substantial cash and cash equivalents of $587.0 million and a total debt obligation of $846.6 million as of December 31, 2023, compared to the previous year, show a significant increase in leverage. This financial leverage could be a double-edged sword, potentially increasing returns on equity but also amplifying risks, particularly if interest rates rise or if there are shifts in market demand.
Merit's focus on the cardiovascular and endoscopy segments aligns with current industry trends towards non-invasive and minimally invasive medical procedures. These trends are driven by technological advancements, an aging population and a heightened focus on patient outcomes and cost-efficiency in healthcare.
The constant currency, organic revenue CAGR of 9.4% and the improvement in non-GAAP operating margin by 440 basis points over the three-year period of the Foundations for Growth Program, reflect operational efficiency and an effective growth strategy. The company's ability to exceed the financial targets set for this period indicates strong execution and a viable product portfolio.
The projected constant currency, organic revenue CAGR of at least 5% through the new 'Continued Growth Initiatives' Program suggests a more conservative growth outlook for the next three years. This could be due to anticipated market saturation, increased competition, or regulatory challenges. Nonetheless, aiming for non-GAAP operating margins of at least 20% and cumulative free cash flow of more than $400 million indicates a focus on profitability and financial health.
- Q4 2023 reported revenue of
$324.5 million , up10.6% year-over-year - Q4 2023 constant currency revenue* up
10.3% year-over-year - Q4 2023 constant currency revenue, organic* up
8.3% year-over-year - Q4 2023 GAAP operating margin of
10.4% , compared to10.4% in Q4 2022 - Q4 2023 non-GAAP operating margin* of
18.2% , compared to17.8% in Q4 2022 - Q4 2023 GAAP EPS
$0.47 , compared to$0.58 in Q4 2022 - Q4 2023 non-GAAP EPS*
$0.81 , compared to$0.79 in Q4 2022 - Issues fiscal year 2024 financial guidance
* Constant currency revenue; constant currency revenue, organic; non-GAAP EPS; non-GAAP net income; non-GAAP operating income and margin; non-GAAP gross profit and margin; and free cash flow are non-GAAP financial measures. A reconciliation of these financial measures to their most directly comparable GAAP financial measures is included under the heading “Non-GAAP Financial Measures” below.
SOUTH JORDAN, Utah, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced revenue of
Merit’s revenue by operating segment and product category for the three and twelve-month periods ended December 31, 2023 and 2022 was as follows (unaudited; in thousands, except for percentages):
| Three Months Ended | |||||||||||||||||||
| Reported | Constant Currency * | ||||||||||||||||||
| December 31, | Impact of foreign | December 31, | |||||||||||||||||
| 2023 | 2022 | % Change | exchange | 2023 | % Change | ||||||||||||||
| Cardiovascular | |||||||||||||||||||
| Peripheral Intervention | $ | 134,143 | $ | 112,384 | 19.4 | % | $ | (444 | ) | $ | 133,699 | 19.0 | % | ||||||
| Cardiac Intervention | 90,242 | 85,277 | 5.8 | % | (174 | ) | 90,068 | 5.6 | % | ||||||||||
| Custom Procedural Solutions | 49,624 | 49,147 | 1.0 | % | (67 | ) | 49,557 | 0.8 | % | ||||||||||
| OEM | 41,216 | 38,861 | 6.1 | % | (130 | ) | 41,086 | 5.7 | % | ||||||||||
| Total | 315,225 | 285,669 | 10.3 | % | (815 | ) | 314,410 | 10.1 | % | ||||||||||
| Endoscopy | |||||||||||||||||||
| Endoscopy Devices | 9,290 | 7,746 | 19.9 | % | 5 | 9,295 | 20.0 | % | |||||||||||
| Total | $ | 324,515 | $ | 293,415 | 10.6 | % | $ | (810 | ) | $ | 323,705 | 10.3 | % | ||||||
| Year Ended | |||||||||||||||||||
| Reported | Constant Currency * | ||||||||||||||||||
| December 31, | Impact of foreign | December 31, | |||||||||||||||||
| 2023 | 2022 | % Change | exchange | 2023 | % Change | ||||||||||||||
| Cardiovascular | |||||||||||||||||||
| Peripheral Intervention | $ | 502,220 | $ | 439,810 | 14.2 | % | $ | 2,140 | $ | 504,360 | 14.7 | % | |||||||
| Cardiac Intervention | 358,451 | 343,186 | 4.4 | % | 3,040 | 361,491 | 5.3 | % | |||||||||||
| Custom Procedural Solutions | 195,333 | 190,194 | 2.7 | % | 1,478 | 196,811 | 3.5 | % | |||||||||||
| OEM | 164,556 | 145,034 | 13.5 | % | (293 | ) | 164,263 | 13.3 | % | ||||||||||
| Total | 1,220,560 | 1,118,224 | 9.2 | % | 6,365 | 1,226,925 | 9.7 | % | |||||||||||
| Endoscopy | |||||||||||||||||||
| Endoscopy Devices | 36,806 | 32,757 | 12.4 | % | 75 | 36,881 | 12.6 | % | |||||||||||
| Total | $ | 1,257,366 | $ | 1,150,981 | 9.2 | % | $ | 6,440 | $ | 1,263,806 | 9.8 | % | |||||||
Merit’s GAAP gross margin for the fourth quarter of 2023 was
Merit’s GAAP net income for the fourth quarter of 2023 was
“We delivered better-than-expected revenue and financial results in the fourth quarter,” said Fred P. Lampropoulos, Merit’s Chairman and Chief Executive Officer. “Our constant currency, organic, revenue increased
Mr. Lampropoulos continued: “We are introducing 2024 financial guidance which reflects confidence in our team’s ability to deliver continued strong execution, stable constant currency growth, improving profitability and solid free cash flow generation. We also intend to build upon the significant progress we made in our FFG Program. As detailed in a separate press release this afternoon, we are introducing the “Continued Growth Initiatives” Program and new multi-year financial targets for the three-year period ending December 31, 2026. We believe the successful execution of our 3-year “CGI” Program will result in a constant currency, organic revenue CAGR of at least
As of December 31, 2023, Merit had cash and cash equivalents of
Fiscal Year 2024 Financial Guidance
Based upon the information currently available to Merit’s management, for the year ending December 31, 2024, absent material acquisitions, non-recurring transactions or other factors beyond Merit’s current expectations, Merit expects the following:
Revenue and Earnings Guidance*
| Prior Year (As Reported) | Guidance | ||||
| Year Ended | Year Ending | % Change | |||
| Financial Measure | December 31, 2023 | December 31, 2024 | Y/Y | ||
| Net Sales | |||||
| Cardiovascular Segment | |||||
| Endoscopy Segment | |||||
| Non-GAAP | |||||
| Earnings Per Share | |||||
*Percentage figures approximated; dollar figures may not foot due to rounding
2024 Net Sales Guidance - % Change from Prior Year (Constant Currency) Reconciliation*
| Updated Guidance | ||||||
| Low | High | |||||
| 2024 Net Sales Guidance - % Change from Prior Year (GAAP) | 4.3 | % | 5.4 | % | ||
| Estimated impact of foreign currency exchange rate fluctuations | 0.5 | % | 0.5 | % | ||
| 2024 Net Sales Guidance - % Change from Prior Year (Constant Currency) | 4.8 | % | 5.9 | % | ||
*Percentage figures approximated and may not foot due to rounding
Merit does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures (other than revenue) because Merit is unable to predict with reasonable certainty the financial impact of items such as expenses related to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain severance expenses, performance-based stock compensation expenses, corporate transformation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, Merit is unable to address the significance of the unavailable information, which could be material to future results. Specifically, Merit is not, without unreasonable effort, able to reliably predict the impact of these items and Merit believes inclusion of a reconciliation of these forward-looking non-GAAP measures to their GAAP counterparts could be confusing to investors or cause undue reliance.
Merit’s financial guidance for the year ending December 31, 2024 is subject to risks and uncertainties identified in this release and Merit’s filings with the U.S. Securities and Exchange Commission (the “SEC”).
CONFERENCE CALL
Merit will hold its investor conference call today, Wednesday, February 28, 2024, at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck will also be available at merit.com.
CONSOLIDATED BALANCE SHEETS
(in thousands)
| December 31, | December 31, | |||||||
| 2023 | 2022 | |||||||
| ASSETS | (unaudited) | |||||||
| Current Assets | ||||||||
| Cash and cash equivalents | $ | 587,036 | $ | 58,408 | ||||
| Trade receivables, net | 177,885 | 164,677 | ||||||
| Other receivables | 10,517 | 12,992 | ||||||
| Inventories | 303,871 | 265,991 | ||||||
| Prepaid expenses and other assets | 24,286 | 22,324 | ||||||
| Prepaid income taxes | 4,016 | 3,913 | ||||||
| Income tax refund receivables | 859 | 779 | ||||||
| Total current assets | 1,108,470 | 529,084 | ||||||
| Property and equipment, net | 383,523 | 382,976 | ||||||
| Intangible assets, net | 325,883 | 275,872 | ||||||
| Goodwill | 382,240 | 359,821 | ||||||
| Deferred income tax assets | 7,288 | 6,599 | ||||||
| Operating lease right-of-use assets | 63,047 | 65,262 | ||||||
| Other assets | 54,793 | 44,352 | ||||||
| Total Assets | $ | 2,325,244 | $ | 1,663,966 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current Liabilities | ||||||||
| Trade payables | $ | 65,944 | $ | 68,504 | ||||
| Accrued expenses | 120,447 | 123,189 | ||||||
| Current portion of long-term debt | — | 11,250 | ||||||
| Current operating lease liabilities | 12,087 | 11,005 | ||||||
| Income taxes payable | 5,086 | 6,697 | ||||||
| Total current liabilities | 203,564 | 220,645 | ||||||
| Long-term debt | 823,013 | 186,759 | ||||||
| Deferred income tax liabilities | 5,547 | 18,462 | ||||||
| Long-term income taxes payable | 347 | 347 | ||||||
| Liabilities related to unrecognized tax benefits | 1,912 | 1,912 | ||||||
| Deferred compensation payable | 17,167 | 15,264 | ||||||
| Deferred credits | 1,605 | 1,708 | ||||||
| Long-term operating lease liabilities | 56,259 | 59,736 | ||||||
| Other long-term obligations | 13,830 | 14,736 | ||||||
| Total liabilities | 1,123,244 | 519,569 | ||||||
| Stockholders' Equity | ||||||||
| Common stock | 638,150 | 675,174 | ||||||
| Retained earnings | 575,184 | 480,773 | ||||||
| Accumulated other comprehensive loss | (11,334 | ) | (11,550 | ) | ||||
| Total stockholders' equity | 1,202,000 | 1,144,397 | ||||||
| Total Liabilities and Stockholders' Equity | $ | 2,325,244 | $ | 1,663,966 | ||||
CONSOLIDATED STATEMENTS OF INCOME
(Unaudited, in thousands except per share amounts)
| Three Months Ended | Year Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Net sales | $ | 324,515 | $ | 293,415 | $ | 1,257,366 | $ | 1,150,981 | ||||||||
| Cost of sales | 173,986 | 158,863 | 673,494 | 631,882 | ||||||||||||
| Gross profit | 150,529 | 134,552 | 583,872 | 519,099 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Selling, general and administrative | 95,751 | 83,243 | 373,676 | 342,525 | ||||||||||||
| Research and development | 21,639 | 20,436 | 82,728 | 75,510 | ||||||||||||
| Impairment charges | — | 547 | 270 | 2,219 | ||||||||||||
| Contingent consideration (benefit) expense | (473 | ) | (91 | ) | 1,704 | 4,611 | ||||||||||
| Acquired in-process research and development | — | — | 1,550 | 6,671 | ||||||||||||
| Total operating expenses | 116,917 | 104,135 | 459,928 | 431,536 | ||||||||||||
| Income from operations | 33,612 | 30,417 | 123,944 | 87,563 | ||||||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 1,923 | 123 | 2,456 | 439 | ||||||||||||
| Interest expense | (4,977 | ) | (2,158 | ) | (15,511 | ) | (6,339 | ) | ||||||||
| Other income (expense) — net | 909 | 1,773 | 1,200 | 966 | ||||||||||||
| Total other expense — net | (2,145 | ) | (262 | ) | (11,855 | ) | (4,934 | ) | ||||||||
| Income before income taxes | 31,467 | 30,155 | 112,089 | 82,629 | ||||||||||||
| Income tax (benefit) expense | 3,838 | (3,246 | ) | 17,678 | 8,113 | |||||||||||
| Net income | $ | 27,629 | $ | 33,401 | $ | 94,411 | $ | 74,516 | ||||||||
| Earnings per common share | ||||||||||||||||
| Basic | $ | 0.48 | $ | 0.58 | $ | 1.64 | $ | 1.31 | ||||||||
| Diluted | $ | 0.47 | $ | 0.58 | $ | 1.62 | $ | 1.29 | ||||||||
| Weighted average shares outstanding | ||||||||||||||||
| Basic | 57,793 | 57,098 | 57,593 | 56,806 | ||||||||||||
| Diluted | 58,385 | 57,963 | 58,356 | 57,671 | ||||||||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, in thousands)
| Year Ended | ||||||||
| December 31, | ||||||||
| 2023 | 2022 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net income | $ | 94,411 | $ | 74,516 | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 89,985 | 81,804 | ||||||
| (Gain) loss on disposition of business | (431 | ) | 1,417 | |||||
| Write-off of certain intangible assets and other long-term assets | 506 | 2,281 | ||||||
| Amortization of right-of-use operating lease assets | 11,307 | 10,394 | ||||||
| Fair value adjustments related to contingent consideration liabilities | 1,704 | 4,611 | ||||||
| Acquired in-process research and development | 1,550 | 6,671 | ||||||
| Deferred income taxes | (12,643 | ) | (14,924 | ) | ||||
| Stock-based compensation expense | 21,333 | 18,042 | ||||||
| Other adjustments | 7,451 | 877 | ||||||
| Changes in operating assets and liabilities, net of acquisitions and divestitures | (70,022 | ) | (71,398 | ) | ||||
| Total adjustments | 50,740 | 39,775 | ||||||
| Net cash, cash equivalents, and restricted cash provided by operating activities | 145,151 | 114,291 | ||||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Capital expenditures for property and equipment | (34,290 | ) | (45,029 | ) | ||||
| Cash paid in acquisitions, net of cash acquired | (138,278 | ) | (8,287 | ) | ||||
| Other investing, net | (2,779 | ) | (4,081 | ) | ||||
| Net cash, cash equivalents, and restricted cash used in investing activities | (175,347 | ) | (57,397 | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from issuance of common stock | 15,584 | 20,070 | ||||||
| Proceeds from (payment of) long-term debt | 619,579 | (44,938 | ) | |||||
| Purchase of capped call option | (66,528 | ) | — | |||||
| Long-term debt issuance costs | (677 | ) | — | |||||
| Contingent payments related to acquisitions | (3,569 | ) | (32,918 | ) | ||||
| Payment of taxes related to an exchange of common stock | (5,123 | ) | (2,474 | ) | ||||
| Net cash, cash equivalents, and restricted cash provided by (used in) financing activities | 559,266 | (60,260 | ) | |||||
| Effect of exchange rates on cash | (484 | ) | (3,826 | ) | ||||
| Net increase (decrease) in cash, cash equivalents and restricted cash | 528,586 | (7,192 | ) | |||||
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH: | ||||||||
| Beginning of period | 60,558 | 67,750 | ||||||
| End of period | $ | 589,144 | $ | 60,558 | ||||
| RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH TO THE CONSOLIDATED BALANCE SHEETS: | ||||||||
| Cash and cash equivalents | 587,036 | 58,408 | ||||||
| Restricted cash reported in prepaid expenses and other current assets | 2,108 | 2,150 | ||||||
| Total cash, cash equivalents and restricted cash | $ | 589,144 | $ | 60,558 | ||||
Non-GAAP Financial Measures
Although Merit’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”), Merit’s management believes that the non-GAAP financial measures referenced in this release provide investors with useful information regarding the underlying business trends and performance of Merit’s ongoing operations and can be useful for period-over-period comparisons of such operations. Non-GAAP financial measures used in this release include:
- constant currency revenue;
- constant currency revenue, organic;
- non-GAAP gross profit and margin;
- non-GAAP operating income and margin;
- non-GAAP net income;
- non-GAAP earnings per share; and
- free cash flow.
Merit’s management team uses these non-GAAP financial measures to evaluate Merit’s profitability and efficiency, to compare operating and financial results to prior periods, to evaluate changes in the results of its operating segments, and to measure and allocate financial resources internally. However, Merit’s management does not consider such non-GAAP measures in isolation or as an alternative to measures determined in accordance with GAAP.
Readers should consider non-GAAP measures used in this release in addition to, not as a substitute for, financial reporting measures prepared in accordance with GAAP. These non-GAAP financial measures generally exclude some, but not all, items that may affect Merit’s net income. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which items are excluded. Merit believes it is useful to exclude such items in the calculation of non-GAAP gross profit and margin, non-GAAP operating income and margin, non-GAAP net income, and non-GAAP earnings per share (in each case, as further illustrated in the reconciliation tables below) because such amounts in any specific period may not directly correlate to the underlying performance of Merit’s business operations and can vary significantly between periods as a result of factors such as acquisition or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain severance expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, corporate transformation expenses, governmental proceedings or changes in tax or industry regulations, gains or losses on disposal of certain assets, and debt issuance costs. Merit may incur similar types of expenses in the future, and the non-GAAP financial information included in this release should not be viewed as a statement or indication that these types of expenses will not recur. Additionally, the non-GAAP financial measures used in this release may not be comparable with similarly titled measures of other companies. Merit urges readers to review the reconciliations of its non-GAAP financial measures to their most directly comparable GAAP financial measures included herein, and not to rely on any single financial measure to evaluate Merit’s business or results of operations.
Constant Currency Revenue
Merit’s constant currency revenue is prepared by converting the current-period reported revenue of subsidiaries whose functional currency is a currency other than the U.S. dollar at the applicable foreign exchange rates in effect during the comparable prior-year period and adjusting for the effects of hedging transactions on reported revenue, which are recorded in the U.S. dollar. The constant currency revenue adjustments of (
Constant Currency Revenue, Organic
Merit’s constant currency revenue, organic, is defined, with respect to prior fiscal year periods, as GAAP revenue. With respect to current fiscal year periods, constant currency revenue, organic, is defined as constant currency revenue (as defined above), less revenue from certain acquisitions. For the three and twelve-month periods ended December 31, 2023, Merit’s constant currency revenue, organic, excludes revenues attributable to certain assets acquired from AngioDynamics, Inc. (“AngioDynamics”) in June 2023.
Non-GAAP Gross Profit and Margin
Non-GAAP gross profit is calculated by reducing GAAP cost of sales by amounts recorded for amortization of intangible assets, corporate restructuring charges, and inventory mark-up related to acquisitions. Non-GAAP gross margin is calculated by dividing non-GAAP gross profit by reported net sales.
Non-GAAP Operating Income and Margin
Non-GAAP operating income is calculated by adjusting GAAP operating income for certain items which are deemed by Merit’s management to be outside of core operations and vary in amount and frequency among periods, such as expenses related to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain severance expenses, performance-based stock compensation expenses, corporate transformation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations, as well as other items referenced in the tables below. Non-GAAP operating margin is calculated by dividing non-GAAP operating income by reported net sales.
Non-GAAP Net Income
Non-GAAP net income is calculated by adjusting GAAP net income for the items set forth in the definition of non-GAAP operating income above, as well as for expenses related to debt issuance costs, gains or losses on disposal of certain assets, changes in tax regulations, and other items set forth in the tables below.
Non-GAAP EPS
Non-GAAP EPS is defined as non-GAAP net income divided by the diluted shares outstanding for the corresponding period.
Free Cash Flow
Free cash flow is defined as cash flow from operations calculated in accordance with GAAP, less capital expenditures for property and equipment calculated in accordance with GAAP, as set forth in the consolidated statement of cash flows.
Non-GAAP Financial Measure Reconciliations
The following tables set forth supplemental financial data and corresponding reconciliations of non-GAAP financial measures to Merit’s corresponding financial measures prepared in accordance with GAAP, in each case, for the three and twelve-month periods ended December 31, 2023 and 2022. The non-GAAP income adjustments referenced in the following tables do not reflect non-performance-based stock compensation expense of approximately
Reconciliation of GAAP Net Income to Non-GAAP Net Income
(Unaudited, in thousands except per share amounts)
| Three Months Ended | ||||||||||||||||
| December 31, 2023 | ||||||||||||||||
| Pre-Tax | Tax Impact | After-Tax | Per Share Impact | |||||||||||||
| GAAP net income | $ | 31,467 | $ | (3,838 | ) | $ | 27,629 | $ | 0.47 | |||||||
| Non-GAAP adjustments: | ||||||||||||||||
| Cost of Sales | ||||||||||||||||
| Amortization of intangibles | 12,611 | (3,032 | ) | 9,579 | 0.16 | |||||||||||
| Corporate restructuring (a) | 448 | (108 | ) | 340 | 0.01 | |||||||||||
| Inventory mark-up related to acquisitions | 68 | (17 | ) | 51 | 0.00 | |||||||||||
| Operating Expenses | ||||||||||||||||
| Contingent consideration benefit | (473 | ) | 74 | (399 | ) | (0.01 | ) | |||||||||
| Amortization of intangibles | 2,334 | (562 | ) | 1,772 | 0.03 | |||||||||||
| Performance-based share-based compensation (b) | 2,459 | (350 | ) | 2,109 | 0.04 | |||||||||||
| Corporate transformation and restructuring (c) | 5,162 | (1,237 | ) | 3,925 | 0.07 | |||||||||||
| Acquisition-related | 68 | (16 | ) | 52 | 0.00 | |||||||||||
| Medical Device Regulation expenses (d) | 2,710 | (651 | ) | 2,059 | 0.04 | |||||||||||
| Other (e) | 41 | (10 | ) | 31 | 0.00 | |||||||||||
| Other (Income) Expense | ||||||||||||||||
| Amortization of long-term debt issuance costs | 585 | (140 | ) | 445 | 0.01 | |||||||||||
| Gain on disposal of business unit | (431 | ) | — | (431 | ) | (0.01 | ) | |||||||||
| Non-GAAP net income | $ | 57,049 | $ | (9,887 | ) | $ | 47,162 | $ | 0.81 | |||||||
| Diluted shares | 58,385 | |||||||||||||||
| Three Months Ended | ||||||||||||||||
| December 31, 2022 | ||||||||||||||||
| Pre-Tax | Tax Impact | After-Tax | Per Share Impact | |||||||||||||
| GAAP net income | $ | 30,155 | $ | 3,246 | $ | 33,401 | $ | 0.58 | ||||||||
| Non-GAAP adjustments: | ||||||||||||||||
| Cost of Sales | ||||||||||||||||
| Amortization of intangibles | 10,615 | (2,602 | ) | 8,013 | 0.14 | |||||||||||
| Operating Expenses | ||||||||||||||||
| Contingent consideration benefit | (91 | ) | 31 | (60 | ) | (0.00 | ) | |||||||||
| Impairment charges | 547 | — | 547 | 0.01 | ||||||||||||
| Amortization of intangibles | 1,551 | (382 | ) | 1,169 | 0.02 | |||||||||||
| Performance-based share-based compensation (b) | 1,152 | (133 | ) | 1,019 | 0.02 | |||||||||||
| Corporate transformation and restructuring (c) | 3,325 | (814 | ) | 2,511 | 0.04 | |||||||||||
| Acquisition-related | 213 | (52 | ) | 161 | 0.00 | |||||||||||
| Medical Device Regulation expenses (d) | 4,482 | (1,097 | ) | 3,385 | 0.06 | |||||||||||
| Other (e) | 121 | (30 | ) | 91 | 0.00 | |||||||||||
| Other (Income) Expense | ||||||||||||||||
| Amortization of long-term debt issuance costs | 151 | (37 | ) | 114 | 0.00 | |||||||||||
| Loss on disposal of business unit | 17 | 3 | 20 | 0.00 | ||||||||||||
| Tax expense related to restructuring (f) | — | (4,324 | ) | (4,324 | ) | (0.07 | ) | |||||||||
| Non-GAAP net income | $ | 52,238 | $ | (6,191 | ) | $ | 46,047 | $ | 0.79 | |||||||
| Diluted shares | 57,963 | |||||||||||||||
| Note: Certain per share impacts may not sum to totals due to rounding. | ||||||||||||||||
Reconciliation of GAAP Net Income to Non-GAAP Net Income
(Unaudited, in thousands except per share amounts)
| Year Ended | ||||||||||||||||
| December 31, 2023 | ||||||||||||||||
| Pre-Tax | Tax Impact | After-Tax | Per Share Impact | |||||||||||||
| GAAP net income | $ | 112,089 | $ | (17,678 | ) | $ | 94,411 | $ | 1.62 | |||||||
| Non-GAAP adjustments: | ||||||||||||||||
| Cost of Sales | ||||||||||||||||
| Amortization of intangibles | 47,795 | (11,492 | ) | 36,303 | 0.62 | |||||||||||
| Corporate restructuring (a) | 448 | (108 | ) | 340 | 0.01 | |||||||||||
| Inventory mark-up related to acquisitions | 2,069 | (497 | ) | 1,572 | 0.03 | |||||||||||
| Operating Expenses | ||||||||||||||||
| Contingent consideration expense | 1,704 | (47 | ) | 1,657 | 0.03 | |||||||||||
| Impairment charges | 270 | — | 270 | 0.00 | ||||||||||||
| Amortization of intangibles | 8,293 | (1,998 | ) | 6,295 | 0.11 | |||||||||||
| Performance-based share-based compensation (b) | 8,526 | (1,121 | ) | 7,405 | 0.13 | |||||||||||
| Corporate transformation and restructuring (c) | 19,365 | (4,646 | ) | 14,719 | 0.25 | |||||||||||
| Acquisition-related | 5,286 | (1,269 | ) | 4,017 | 0.07 | |||||||||||
| Medical Device Regulation expenses (d) | 11,822 | (2,838 | ) | 8,984 | 0.15 | |||||||||||
| Other (e) | (1,268 | ) | 304 | (964 | ) | (0.02 | ) | |||||||||
| Other (Income) Expense | ||||||||||||||||
| Amortization of long-term debt issuance costs | 1,639 | (393 | ) | 1,246 | 0.02 | |||||||||||
| Gain on disposal of business unit | (431 | ) | — | (431 | ) | (0.01 | ) | |||||||||
| Non-GAAP net income | $ | 217,607 | $ | (41,783 | ) | $ | 175,824 | $ | 3.01 | |||||||
| Diluted shares | 58,356 | |||||||||||||||
| Year Ended | |||||||||||||||
| December 31, 2022 | |||||||||||||||
| Pre-Tax | Tax Impact | After-Tax | Per Share Impact | ||||||||||||
| GAAP net income | $ | 82,629 | $ | (8,113 | ) | $ | 74,516 | $ | 1.29 | ||||||
| Non-GAAP adjustments: | |||||||||||||||
| Cost of Sales | |||||||||||||||
| Amortization of intangibles | 42,154 | (10,335 | ) | 31,819 | 0.55 | ||||||||||
| Operating Expenses | |||||||||||||||
| Contingent consideration expense | 4,611 | 14 | 4,625 | 0.08 | |||||||||||
| Impairment charges | 2,219 | (318 | ) | 1,901 | 0.03 | ||||||||||
| Amortization of intangibles | 6,300 | (1,558 | ) | 4,742 | 0.08 | ||||||||||
| Performance-based share-based compensation (b) | 5,506 | (546 | ) | 4,960 | 0.09 | ||||||||||
| Corporate transformation and restructuring (c) | 23,757 | (5,516 | ) | 18,241 | 0.32 | ||||||||||
| Acquisition-related | 2,114 | (517 | ) | 1,597 | 0.03 | ||||||||||
| Medical Device Regulation expenses (d) | 12,933 | (3,166 | ) | 9,767 | 0.17 | ||||||||||
| Other (e) | 7,966 | (1,893 | ) | 6,073 | 0.11 | ||||||||||
| Other (Income) Expense | |||||||||||||||
| Amortization of long-term debt issuance costs | 604 | (148 | ) | 456 | 0.01 | ||||||||||
| Loss on disposal of business unit | 1,407 | (29 | ) | 1,378 | 0.02 | ||||||||||
| Tax expense related to restructuring (f) | — | (4,324 | ) | (4,324 | ) | (0.07 | ) | ||||||||
| Non-GAAP net income | $ | 192,200 | $ | (36,449 | ) | $ | 155,751 | $ | 2.70 | ||||||
| Diluted shares | 57,671 | ||||||||||||||
| Note: Certain per share impacts may not sum to totals due to rounding. | |||||||||||||||
Reconciliation of Reported Operating Income to Non-GAAP Operating Income
(Unaudited, in thousands except percentages)
| Three Months Ended | Three Months Ended | Year Ended | Year Ended | ||||||||||||||||||||||||
| December 31, 2023 | December 31, 2022 | December 31, 2023 | December 31, 2022 | ||||||||||||||||||||||||
| Amounts | % Sales | Amounts | % Sales | Amounts | % Sales | Amounts | % Sales | ||||||||||||||||||||
| Net Sales as Reported | $ | 324,515 | $ | 293,415 | $ | 1,257,366 | $ | 1,150,981 | |||||||||||||||||||
| GAAP Operating Income | 33,612 | 10.4 | % | 30,417 | 10.4 | % | 123,944 | 9.9 | % | 87,563 | 7.6 | % | |||||||||||||||
| Cost of Sales | |||||||||||||||||||||||||||
| Amortization of intangibles | 12,611 | 3.9 | % | 10,615 | 3.6 | % | 47,795 | 3.8 | % | 42,154 | 3.7 | % | |||||||||||||||
| Corporate restructuring (a) | 448 | 0.1 | % | — | — | 448 | 0.0 | % | — | — | |||||||||||||||||
| Inventory mark-up related to acquisitions | 68 | 0.0 | % | — | — | 2,069 | 0.2 | % | — | — | |||||||||||||||||
| Operating Expenses | |||||||||||||||||||||||||||
| Contingent consideration (benefit) expense | (473 | ) | (0.1 | )% | (91 | ) | (0.0 | )% | 1,704 | 0.1 | % | 4,611 | 0.4 | % | |||||||||||||
| Impairment charges | — | — | 547 | 0.2 | % | 270 | 0.0 | % | 2,219 | 0.2 | % | ||||||||||||||||
| Amortization of intangibles | 2,334 | 0.7 | % | 1,551 | 0.5 | % | 8,293 | 0.7 | % | 6,300 | 0.5 | % | |||||||||||||||
| Performance-based share-based compensation (b) | 2,459 | 0.8 | % | 1,152 | 0.4 | % | 8,526 | 0.7 | % | 5,506 | 0.5 | % | |||||||||||||||
| Corporate transformation and restructuring (c) | 5,162 | 1.6 | % | 3,325 | 1.1 | % | 19,365 | 1.5 | % | 23,757 | 2.1 | % | |||||||||||||||
| Acquisition-related | 68 | 0.0 | % | 213 | 0.1 | % | 5,286 | 0.4 | % | 2,114 | 0.2 | % | |||||||||||||||
| Medical Device Regulation expenses (d) | 2,710 | 0.8 | % | 4,482 | 1.5 | % | 11,822 | 0.9 | % | 12,933 | 1.1 | % | |||||||||||||||
| Other (e) | 41 | 0.0 | % | 121 | 0.0 | % | (1,268 | ) | (0.1 | )% | 7,966 | 0.7 | % | ||||||||||||||
| Non-GAAP Operating Income | $ | 59,040 | 18.2 | $ | 52,332 | 17.8 | $ | 228,254 | 18.2 | $ | 195,123 | 17.0 | % | ||||||||||||||
| Note: Certain percentages may not sum to totals due to rounding. | |||
| a) | Represents corporate restructuring charges reflected within cost of sales including the write-off of inventory related to the divestiture or exit of certain businesses or product lines. | ||
| b) | Represents performance-based share-based compensation expense, including stock-settled and cash-settled awards. | ||
| c) | Includes consulting expenses related to the Foundations for Growth Program, | ||
| d) | Represents incremental expenses incurred to comply with the E.U. Medical Device Regulation (“MDR”). | ||
| e) | The 2023 periods include insurance reimbursement of approximately | ||
| f) | Represents an adjustment to our deferred withholding tax liability on unremitted foreign earnings as a result of the restructuring of certain international subsidiaries in 2022. | ||
Reconciliation of Reported Revenue to Constant Currency Revenue (Non-GAAP), and Constant Currency Revenue, Organic (Non-GAAP)
(Unaudited, in thousands except percentages)
| Three Months Ended | Year Ended | |||||||||||||||||
| December 31, | December 31, | |||||||||||||||||
| % Change | 2023 | 2022 | % Change | 2023 | 2022 | |||||||||||||
| Reported Revenue | 10.6 | % | $ | 324,515 | $ | 293,415 | 9.2 | % | $ | 1,257,366 | $ | 1,150,981 | ||||||
| Add: Impact of foreign exchange | (810 | ) | — | 6,440 | — | |||||||||||||
| Constant Currency Revenue (a) | 10.3 | % | $ | 323,705 | $ | 293,415 | 9.8 | % | $ | 1,263,806 | $ | 1,150,981 | ||||||
| Less: Revenue from certain acquisitions | (6,079 | ) | — | (14,365 | ) | — | ||||||||||||
| Constant Currency Revenue, Organic (a) | 8.3 | % | $ | 317,626 | $ | 293,415 | 8.6 | % | $ | 1,249,441 | $ | 1,150,981 | ||||||
| (a) A non-GAAP financial measure. For a definition of this and other non-GAAP financial measures, see the section of this release entitled “Non-GAAP Financial Measures.” | ||||||||||||||||||
Reconciliation of Reported Gross Margin to Non-GAAP Gross Margin (Non-GAAP)
(Unaudited, as a percentage of reported revenue)
| Three Months Ended | Year Ended | |||||||||||
| December 31, | December 31, | |||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||
| Reported Gross Margin | 46.4 | % | 45.9 | % | 46.4 | % | 45.1 | % | ||||
| Add back impact of: | ||||||||||||
| Amortization of intangibles | 3.9 | % | 3.6 | % | 3.8 | % | 3.7 | % | ||||
| Corporate restructuring (a) | 0.1 | % | — | 0.0 | % | — | ||||||
| Inventory mark-up related to acquisitions | 0.0 | % | — | 0.2 | % | — | ||||||
| Non-GAAP Gross Margin | 50.4 | % | 49.5 | % | 50.4 | % | 48.8 | % | ||||
| Note: Certain percentages may not sum to totals due to rounding. | |||
| (a) | Represents corporate restructuring charges reflected within cost of sales including the write-off of inventory related to the divestiture or exit of certain businesses or product lines. | ||
ABOUT MERIT
Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling more than 700 individuals. Merit employs approximately 7,000 people worldwide.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
Statements contained in this release which are not purely historical, including, without limitation, statements regarding Merit’s forecasted plans, revenues, net sales, net income (GAAP and non-GAAP), operating income and margin (GAAP and non-GAAP), gross profit and margin (GAAP and non-GAAP), earnings per share (GAAP and non-GAAP), free cash flow and other financial measures, future growth and profit expectations or forecasted economic conditions, or the implementation of, and results which may be achieved through, Merit’s Foundations for Growth Program, Continued Growth Initiatives Program or other expense reduction initiatives, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to risks and uncertainties such as those described in Merit’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report”) and other filings with the SEC. Such risks and uncertainties include inherent risks and uncertainties associated with Merit’s integration of products acquired from AngioDynamics and its ability to achieve anticipated financial results, product development and other anticipated benefits of the AngioDynamics acquisition; uncertainties as to whether Merit will achieve sales, gross and operating margins, net income and earnings per share performance consistent with its forecasts associated with that acquisition; disruptions in Merit’s supply chain, manufacturing or sterilization processes; reduced availability of, and price increases associated with, commodity components and other raw materials; adverse changes in freight, shipping and transportation expenses; negative changes in economic and industry conditions in the United States or other countries, including inflation; risks relating to Merit’s potential inability to successfully manage growth through acquisitions generally, including the inability to effectively integrate acquired operations or products or commercialize technology developed internally or acquired through completed, proposed or future transactions; risks associated with Merit’s ongoing or prospective manufacturing transfers and facility consolidations; fluctuations in interest or foreign currency exchange rates; risks and uncertainties associated with Merit’s information technology systems, including the potential for breaches of security and evolving regulations regarding privacy and data protection; governmental scrutiny and regulation of the medical device industry, including governmental inquiries, investigations and proceedings involving Merit; consequences associated with a Corporate Integrity Agreement executed between Merit and the U.S. Office of Inspector General; difficulties, delays and expenditures relating to development, testing and regulatory approval or clearance of Merit’s products, including the pursuit of approvals under the MDR, and risks that such products may not be developed successfully or approved for commercial use; litigation and other judicial proceedings affecting Merit; the potential of fines, penalties or other adverse consequences if Merit’s employees or agents violate the U.S. Foreign Corrupt Practices Act or other laws or regulations; restrictions on Merit’s liquidity or business operations resulting from its debt agreements; infringement of Merit’s technology or the assertion that Merit’s technology infringes the rights of other parties; product recalls and product liability claims; changes in customer purchasing patterns or the mix of products Merit sells; laws and regulations targeting fraud and abuse in the healthcare industry; potential for significant adverse changes in governing regulations, including reforms to the procedures for approval or clearance of Merit’s products by the U.S. Food & Drug Administration or comparable regulatory authorities in other jurisdictions; changes in tax laws and regulations in the United States or other jurisdictions; termination of relationships with Merit’s suppliers, or failure of such suppliers to perform; concentration of a substantial portion of Merit’s revenues among a few products and procedures; development of new products and technology that could render Merit’s existing or future products obsolete; market acceptance of new products; dependance on distributors to commercialize Merit’s products in various jurisdictions outside the United States; volatility in the market price of Merit’s common stock; modification or limitation of governmental or private insurance reimbursement policies; changes in healthcare policies or markets related to healthcare reform initiatives; failure to comply with applicable environmental laws; changes in key personnel; work stoppage or transportation risks; failure to introduce products in a timely fashion; price and product competition; fluctuations in and obsolescence of inventory; and other factors referenced in the 2023 Annual Report and other materials filed with the SEC.
All subsequent forward-looking statements attributable to Merit or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Actual results will likely differ, and may differ materially, from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results. Those estimates and all other forward-looking statements included in this document are made only as of the date of this document, and except as otherwise required by applicable law, Merit assumes no obligation to update or disclose revisions to estimates and all other forward-looking statements.
TRADEMARKS
Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.
| Contacts: | |
| PR/Media Inquiries: | Investor Inquiries: |
| Teresa Johnson | Mike Piccinino, CFA, IRC |
| Merit Medical | Westwicke – ICR |
| +1-801-208-4295 | +1-443-213-0509 |
| tjohnson@merit.com | mike.piccinino@westwicke.com |
FAQ
What was Merit Medical Systems, Inc.'s reported revenue for Q4 2023?
What was the year-over-year increase in revenue for Merit Medical Systems, Inc. in Q4 2023?
What was the GAAP operating margin for Merit Medical Systems, Inc. in Q4 2023?
What was the non-GAAP operating margin for Merit Medical Systems, Inc. in Q4 2023?
What was the GAAP EPS for Merit Medical Systems, Inc. in Q4 2023?
What was the non-GAAP EPS for Merit Medical Systems, Inc. in Q4 2023?
What financial guidance did Merit Medical Systems, Inc. provide for fiscal year 2024?
How much cash and cash equivalents did Merit Medical Systems, Inc. have as of December 31, 2023?
What were Merit Medical Systems, Inc.'s total debt obligations as of December 31, 2023?
